Identification | Back Directory | [Name]
N-{3-[(diphenylacetyl)amino]propyl}-4-oxo-3,4-dihydro-2-quinazolinecarboxamide | [CAS]
1119503-63-7 | [Synonyms]
JNc-440
(JNc440) N-{3-[(diphenylacetyl)amino]propyl}-4-oxo-3,4-dihydro-2-quinazolinecarboxamide | [Molecular Formula]
C26H24N4O3 | [MOL File]
1119503-63-7.mol | [Molecular Weight]
440.49 |
Hazard Information | Back Directory | [Biological Activity]
JNc-440 is a potent antihypertensive agent. JNc-440 can enhance the interaction of TRPV4 and Ca2+-activated potassium channel 3 (KCa2.3) in endothelial cells. JNc-440 can also enhance vasodilation, and exerted antihypertensive effects in mice[1].
JNc-440 (1 mg/kg; IV; single dosage) improves endothelium-dependent relaxation in small resistance arteries and to lower blood pressure[1]. | [storage]
Store at -20°C | [References]
[1]. He D, et al. Treatment of hypertension by increasing impaired endothelial TRPV4-KCa2.3 interaction. EMBO Mol Med. 2017 Nov;9(11):1491-1503. |
|
Company Name: |
PHARMEKS Ltd.
|
Tel: |
+7 (495) 702-9648 |
Website: |
www.pharmeks.com |
Company Name: |
Specs
|
Tel: |
+31 15 251 8111 |
Website: |
www.specs.net |
|